NasdaqCM:EXASBiotechs
Assessing Exact Sciences (EXAS) Valuation Following Launch of Cancerguard Multi-Cancer Blood Test
If you follow biotech movers in your portfolio, Exact Sciences (EXAS) just made waves by launching Cancerguard, its new multi-cancer early detection blood test in the United States. What sets this announcement apart is that Cancerguard can screen for over 50 cancer types, including those that previously had no recommended screening, and it boasts promising sensitivity and specificity results. The partnership with Quest Diagnostics and the company’s commitment to large-scale real-world...